PROCEPT BioRoboticsPRCT +1.16%70 Days Payable is 56.49 as of Mar. 2026, which is 3% above its 10-year median of 54.60. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $91.98 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 69.31% on this metric.
The historical rank and industry rank for PROCEPT BioRobotics's Days Payable or its related term are showing as below:
PRCT'
s Days Payable Range Over the Past 10 Years
Min: 32.06 Med: 54.6 Max: 65.44
Current: 46.48
During the past 7 years, PROCEPT BioRobotics's highest Days Payable was 65.44. The lowest was 32.06. And the median was 54.60.
PRCT's Days Payable is ranked worse than 69.31% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs PRCT: 46.48
PROCEPT BioRobotics's Days Payable
increased
from Mar. 2025 (45.37) to Mar. 2026 (56.49).
It may suggest that PROCEPT BioRoboticsdelayed paying its suppliers.
PROCEPT BioRobotics Days Payable Related Terms
PROCEPT BioRobotics Days Payable Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, PROCEPT BioRobotics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Days Payable distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PROCEPT BioRobotics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a Days Payable of 56.49 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PROCEPT BioRobotics and its competitors. This is near median its historical median of 54.60. Over the past decade, PROCEPT BioRobotics' Days Payable has ranged from 32.06 to 65.44. According to the industry distribution chart, PROCEPT BioRobotics ranks #551 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 69.3%.
Is PROCEPT BioRobotics' Days Payable too high?
PROCEPT BioRobotics' current Days Payable of 56.49 is near median its 10-year median of 54.60. Over the past 10 years, this metric has ranged from a low of 32.06 to a high of 65.44. The Medical Devices & Instruments industry median Days Payable is 67.87. PROCEPT BioRobotics' value of 56.49 is 16.8% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #551 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Days Payable compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #551 out of 795 companies for Days Payable. This places PROCEPT BioRobotics in the lower half of its industry. The industry median Days Payable is 67.87. PROCEPT BioRobotics' value of 56.49 is 16.8% below this benchmark. Historically, PROCEPT BioRobotics' own Days Payable has ranged from 32.06 to 65.44 over the past decade. While the company's 10-year median is 54.60 vs. the industry median of 67.87, PROCEPT BioRobotics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Days Payable of 56.49 is 16.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Days Payable is 56.49, which is near median its own 10-year median of 54.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $91.98, compared to a current price of $20.85 — trading 77.3% below its estimated fair value. The current Days Payable is 56.49, which is near median its 10-year median of 54.60 and 16.8% below the Medical Devices & Instruments industry median of 67.87. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Days Payable is 56.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $20.85 is trading 77.3% below its estimated GF Value™ of $91.98.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Days Payable: 56.49 (near median its 10-year median of 54.60)
GF Value™: $91.98 vs. price of $20.85 (77.3% below fair value)
Industry Position: 16.8% below the Medical Devices & Instruments median (#551 of 795)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
